Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label Pharmacokinetic Study in Healthy Lactating Women After Two Oral Doses of Ibrexafungerp Administered on a Single Day

NCT06954493 is registered in ClinicalTrials.gov with Scynexis, Inc. as lead sponsor.

NCT NCT06954493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06954493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label Pharmacokinetic Study in Healthy Lactating Women After Two Oral Doses of Ibrexafungerp Administered on a Single Day
Lead sponsor
Scynexis, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 12, 2023
Completion date
November 1, 2023
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

candida infection, vaginal candidiasis, vulvovaginal candidiasis